oculopharyngeal muscular dystrophy

(redirected from OPMD)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to oculopharyngeal muscular dystrophy

a form of muscular dystrophy that usually begins between early adulthood and middle age and first affects muscles of the eyelid and throat

References in periodicals archive ?
The present study is thus aimed to determine the usefulness of serum and salivary IgA as a diagnostic and prognostic marker in OPMD and OSCC.
Hypoxia plays a critical role in oral cancers, pharyngeal cancers, and OPMD [118].
Participants living with OPMD, a late onset condition causing ptosis and dysphagia, identified that their symptoms negatively impacted them physiologically, psychologically, and socially (Krause-Bachand, & Koopman, 2008).
OPMD's primary mission is to manage the Army's officer personnel, including assignment and career management of officers worldwide.
POC is Major Dave Holbrook, majors' assignment officer, Engineer Branch, OPMD, PERSCOM.
OPMD is a neuromuscular disease caused by mutations in the gene coding for polyA-binding protein nuclear 1 (PABPN1).
Oculopharyngeal muscular dystrophy (OPMD) (OMIM #164300) is a late-onset (>45 years) myopathy characterised by progressive ptosis, dysphagia and varying degrees of proximal muscle weakness.
One of the major risk factors associated with the high prevalence of head and neck cancer and oral potentially malignant diseases (OPMD) in this region is smokeless tobacco (SLT) [9].
Infantry Branch (OPMD) will assign captains to a type of infantry unit different from the type they served in as lieutenants to expand the officers' experience early in their careers.
Bioblast Pharma (ORPN) announced the sale of its Trehalose clinical development programs, including its advanced phase 2 clinical program of Trehalose to treat Oculoharyngeal Muscular Dystrophy, or OPMD, to Seelos Therapeutics (SEEL), a clinical-stage biopharmaceutical company.
(ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) has received US Food and Drug Administration orphan drug designation for BB-301, its DNA directed RNA interference (ddRNAi) therapeutic for the treatment of oculopharyngeal muscular dystrophy (OPMD), the company said.
Biotechnology company Benitec Biopharma Limited (ASX:BLT) (NASDAQ:BNTC) (NASDAQ:BNTCW) reported on Tuesday the receipt of European Commission orphan drug designation for BB-301, to treat patients with oculopharyngeal muscular dystrophy (OPMD).
Axovant Sciences announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of oculopharyngeal muscular dystrophy, or OPMD, and has also entered into a research collaboration for the development of five additional gene therapy products in neurological disorders.